S Schenone

Summary

Affiliation: University of Genoa
Country: Italy

Publications

  1. ncbi An update on dual Src/Abl inhibitors
    Francesca Musumeci
    Dipartimento di Scienze Farmaceutiche, University of Genoa, Viale Benedetto XV 3, I 16132 Genova, Italy
    Future Med Chem 4:799-822. 2012
  2. ncbi Antiproliferative and pro-apoptotic effects afforded by novel Src-kinase inhibitors in human neuroblastoma cells
    Michele Navarra
    Pharmaco Biological Department, University of Messina, Viale Annunziata, 98100 Messina, Italy
    BMC Cancer 10:602. 2010
  3. ncbi 2-aryl-3-phenylamino-4,5-dihydro-2h-benz[g]indazoles with analgesic activity
    Silvia Schenone
    Dipartimento di Scienze Farmaceutiche, Facoltà di Farmacia dell Università degli Studi di Genova, Viale Benedetto XV, 3, 16132, Genova, Italy
    Farmaco 58:845-9. 2003
  4. ncbi New insights into small-molecule inhibitors of Bcr-Abl
    S Schenone
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Viale Benedetto XV, 3, I 16132 Genova, Italy
    Med Res Rev 31:1-41. 2011
  5. ncbi Synthesis of 1-(2-chloro-2-phenylethyl)-6-methylthio-1H-pyrazolo[3,4-d]pyrimidines 4-amino substituted and their biological evaluation
    Silvia Schenone
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Viale Benedetto XV, 16132 Genoa, Italy
    Eur J Med Chem 39:153-60. 2004
  6. ncbi Small molecules ATP-competitive inhibitors of FLT3: a chemical overview
    S Schenone
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Viale Benedetto XV, 3, I 16132, Genova, Italy
    Curr Med Chem 15:3113-32. 2008
  7. ncbi New pyrazolo[3,4-d]pyrimidines endowed with A431 antiproliferative activity and inhibitory properties of Src phosphorylation
    S Schenone
    Dipartimento di Scienze Farmaceutiche, Universita di Genova, Viale Benedetto XV, I 16132 Genoa, Italy
    Bioorg Med Chem Lett 14:2511-7. 2004
  8. ncbi Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines
    Silvia Schenone
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Viale Benedetto XV 3, I 16132 Genova, Italy
    Eur J Med Chem 43:2665-76. 2008
  9. ncbi Antiproliferative activity of new 1-aryl-4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives toward the human epidermoid carcinoma A431 cell line
    Silvia Schenone
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Viale Benedetto XV, 16132 Genova, Italy
    Eur J Med Chem 39:939-46. 2004
  10. ncbi Substituted pyrazolo[3,4-b]pyridines as potent A1 adenosine antagonists: synthesis, biological evaluation, and development of an A1 bovine receptor model
    Tiziano Tuccinardi
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Pisa, Via Bonanno 6, 56126 Pisa, Italy
    ChemMedChem 3:898-913. 2008

Collaborators

Detail Information

Publications68

  1. ncbi An update on dual Src/Abl inhibitors
    Francesca Musumeci
    Dipartimento di Scienze Farmaceutiche, University of Genoa, Viale Benedetto XV 3, I 16132 Genova, Italy
    Future Med Chem 4:799-822. 2012
    ..This review is an update on the most important dual inhibitors already in clinical trials and includes information regarding compounds that have appeared in the literature in recent years...
  2. ncbi Antiproliferative and pro-apoptotic effects afforded by novel Src-kinase inhibitors in human neuroblastoma cells
    Michele Navarra
    Pharmaco Biological Department, University of Messina, Viale Annunziata, 98100 Messina, Italy
    BMC Cancer 10:602. 2010
    ..The Src-family tyrosine kinases (SFKs) are a group of proteins involved in cancer development and invasiveness that seem to play an important role in the NB carcinogenesis...
  3. ncbi 2-aryl-3-phenylamino-4,5-dihydro-2h-benz[g]indazoles with analgesic activity
    Silvia Schenone
    Dipartimento di Scienze Farmaceutiche, Facoltà di Farmacia dell Università degli Studi di Genova, Viale Benedetto XV, 3, 16132, Genova, Italy
    Farmaco 58:845-9. 2003
    ..A series of 2-aryl-3-phenylamino-4,5-dihydro-2H-benz[g]indazoles was synthesized and tested for antiarrhythmic, local anaesthetic and analgesic activity. The title compounds showed a good antinociceptive activity...
  4. ncbi New insights into small-molecule inhibitors of Bcr-Abl
    S Schenone
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Viale Benedetto XV, 3, I 16132 Genova, Italy
    Med Res Rev 31:1-41. 2011
    ....
  5. ncbi Synthesis of 1-(2-chloro-2-phenylethyl)-6-methylthio-1H-pyrazolo[3,4-d]pyrimidines 4-amino substituted and their biological evaluation
    Silvia Schenone
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Viale Benedetto XV, 16132 Genoa, Italy
    Eur J Med Chem 39:153-60. 2004
    ....
  6. ncbi Small molecules ATP-competitive inhibitors of FLT3: a chemical overview
    S Schenone
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Viale Benedetto XV, 3, I 16132, Genova, Italy
    Curr Med Chem 15:3113-32. 2008
    ..Our attention will be focused on chemical structures, mechanisms of action and structure-activity relationships...
  7. ncbi New pyrazolo[3,4-d]pyrimidines endowed with A431 antiproliferative activity and inhibitory properties of Src phosphorylation
    S Schenone
    Dipartimento di Scienze Farmaceutiche, Universita di Genova, Viale Benedetto XV, I 16132 Genoa, Italy
    Bioorg Med Chem Lett 14:2511-7. 2004
    ..In particular, 2h was a better inhibitor of Src phosphorylation than the reference compound PP2...
  8. ncbi Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines
    Silvia Schenone
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Viale Benedetto XV 3, I 16132 Genova, Italy
    Eur J Med Chem 43:2665-76. 2008
    ..Docking studies have been also performed to analyze the binding mode of compounds under study and to identify the structural determinants of their interaction with both Src and Abl...
  9. ncbi Antiproliferative activity of new 1-aryl-4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives toward the human epidermoid carcinoma A431 cell line
    Silvia Schenone
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Viale Benedetto XV, 16132 Genova, Italy
    Eur J Med Chem 39:939-46. 2004
    ....
  10. ncbi Substituted pyrazolo[3,4-b]pyridines as potent A1 adenosine antagonists: synthesis, biological evaluation, and development of an A1 bovine receptor model
    Tiziano Tuccinardi
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Pisa, Via Bonanno 6, 56126 Pisa, Italy
    ChemMedChem 3:898-913. 2008
    ..Analysis of the bovine/human A(1)AR affinity profile of ligands supported the hypothesis that such receptors should be characterized by a different size of their binding site, responsible for the different affinity of the antagonists...
  11. ncbi Synthetic SRC-kinase domain inhibitors and their structural requirements
    Silvia Schenone
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Viale Benedetto XV, I 16132, Genova, Italy
    Anticancer Agents Med Chem 7:660-80. 2007
    ..Here, we report several examples of Src kinase domain inhibitors, focusing our attention on chemical structures, structure-activity relationships and mechanism of action...
  12. ncbi SRC inhibitors and angiogenesis
    S Schenone
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Genova, Italy
    Curr Pharm Des 13:2118-28. 2007
    ..Biological data, structures and mechanisms of action of selected molecules, in terms of Src protein-inhibitor interactions, are also reported...
  13. ncbi Antiangiogenic agents: an update on small molecule VEGFR inhibitors
    S Schenone
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Viale Benedetto XV, I 16132, Genova, Italy
    Curr Med Chem 14:2495-516. 2007
    ....
  14. ncbi Last findings on dual inhibitors of abl and SRC tyrosine-kinases
    S Schenone
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Viale Benedetto XV, I 16132 Genoa, Italy
    Mini Rev Med Chem 7:191-201. 2007
    ..For this reason and also for the development of resistance to classical Bcr-Abl inhibitors, various dual Src/Abl inhibitors have been recently synthesized and tested. This mini review will be focused on the latest finding on this matter...
  15. ncbi A1 receptors ligands: past, present and future trends
    S Schenone
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Viale Benedetto XV 3, Genoa, Italy
    Curr Top Med Chem 10:878-901. 2010
    ....
  16. ncbi Novel dual Src/Abl inhibitors for hematologic and solid malignancies
    Silvia Schenone
    University of Genoa, Dipartimento di Scienze Farmaceutiche, Viale Benedetto VX, Genoa, Italy
    Expert Opin Investig Drugs 19:931-45. 2010
    ..The two enzymes share significant sequence homology and remarkable structural resemblance...
  17. ncbi SRC kinase inhibitors: an update on patented compounds
    S Schenone
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Viale Benedetto XV, 3, I 16132 Genova, Italy
    Curr Med Chem 18:5061-78. 2011
    ..However, only the results of clinical trials will show in the near future the most promising compounds...
  18. ncbi O-[2-hydroxy-3-(dialkylamino)propyl]ethers of (+)-1,7,7-trimethyl bicyclo[2.2.1]heptan-2-one oxime (camphor oxime) with analgesic and antiarrhythmic activities
    S Schenone
    Dipartimento di Scienze Farmaceutiche dell Università, Genoa, Italy
    Farmaco 55:495-8. 2000
    ..No significant anti-inflammatory and hypotensive activities were displayed by any of the compounds, whereas several of them are reasonably active as antiarrhythmic and analgesic agents...
  19. ncbi 3-Arylsulphonyl-5-arylamino-1,3,4-thiadiazol-2(3H)ones as anti-inflammatory and analgesic agents
    S Schenone
    Dipartimento di Scienze Farmaceutiche, Facoltà di Farmacia dell Università degli Studi di Genova, Genoa, Italy
    Bioorg Med Chem 9:2149-53. 2001
    ..The analgesic profile of the two series, evaluated by the acetic acid writhing test, showed that compounds 2c, 2f and 2h, in particular, were the most active. Structure-activity relationships are briefly discussed...
  20. ncbi Synthesis and biological data of 4-amino-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl esters, a new series of A1-adenosine receptor (A1AR) ligands
    S Schenone
    Dipartimento di Scienze Farmaceutiche, Facoltà di Farmacia dell Università degli Studi di Genova, Viale Benedetto XV, 3, 16132, Genoa, Italy
    Bioorg Med Chem Lett 11:2529-31. 2001
    ....
  21. ncbi New opportunities to treat the T315I-Bcr-Abl mutant in chronic myeloid leukaemia: tyrosine kinase inhibitors and molecules that act by alternative mechanisms
    S Schenone
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Viale Benedetto XV, 3, I 16132, Genova, Italy
    Curr Med Chem 17:1220-45. 2010
    ..When possible, the review will focus on medicinal chemistry in terms of chemical structure, mechanism of action and structure-activity relationships...
  22. ncbi Fyn kinase in brain diseases and cancer: the search for inhibitors
    S Schenone
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Viale Benedetto XV, 3, I 16132, Genova, Italy
    Curr Med Chem 18:2921-42. 2011
    ....
  23. ncbi ATP-competitive inhibitors of mTOR: an update
    S Schenone
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Viale Benedetto XV 3, I 16132, Genova, Italy
    Curr Med Chem 18:2995-3014. 2011
    ..Also some examples of dual PI3K/mTOR inhibitors, including PI-103, GNE477, WJD008 and GSK2126458 are reported together with their biological and clinical data...
  24. ncbi Using insights into Pim1 structure to design new anticancer drugs
    Silvia Schenone
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Viale Benedetto XV 3, I 16132 Genova, Italy
    Curr Pharm Des 16:3964-78. 2010
    ..This data collection, which to the best of our knowledge was not previously reviewed in such detail, could offer a useful tool for medicinal chemists working in the field of small molecule kinase inhibitors...
  25. ncbi New 1,3,4-thiadiazole derivatives endowed with analgesic and anti-inflammatory activities
    Silvia Schenone
    Dipartimento di Scienze Farmaceutiche, Facolta di Farmacia, Universita degli Studi di Genova, Viale Benedetto XV, 3 16132 Genoa, Italy
    Bioorg Med Chem 14:1698-705. 2006
    ..Ulcerogenic and irritative action on the gastrointestinal mucose, in comparison with indomethacin is low...
  26. ncbi Synthesis and pharmacological screening of novel non-acidic gastroprotective antipyretic anti-inflammatory agents with anti-platelet properties. 5-Alkyl/cycloalkylamino substituted 2-amino-5H-[1]benzopyrano[4,3-d] pyrimidines
    O Bruno
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi, Genova, Italy
    Arzneimittelforschung 50:140-7. 2000
    ..At a 1 mmol/l concentration the compounds under study were as effective as acetylsalicylic acid in inhibiting in vitro platelet aggregation induced by adenosine diphosphate...
  27. ncbi Synthesis and pharmacological evaluation of 2,5-cycloamino-5H-[1]benzopyrano[4,3-d]pyrimidines endowed with in vitro antiplatelet activity
    O Bruno
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi, Viale Benedetto XV, 3 16132, Genova, Italy
    Bioorg Med Chem Lett 11:1397-400. 2001
    ....
  28. ncbi New polycyclic pyrimidine derivatives with antiplatelet in vitro activity: synthesis and pharmacological screening
    O Bruno
    Dipartimento di Scienze Farmaceutiche, , Genova, Italy
    Bioorg Med Chem 9:629-36. 2001
    ..In conclusion, these findings indicate that the 5-pyrrolidino-2-methylthiobenzopyrano[4,3-d]pyrimidine 4d fulfils the chemical requirements to exhibit antiplatelet activity associated with gastroprotective effect...
  29. ncbi 2-Amino/azido/hydrazino-5-alkoxy-5H-[1]benzopyrano[4,3-d]pyrimidines: synthesis and pharmacological evaluation
    O Bruno
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Viale Benedetto XV, 3 16132 Genova, Italy
    Med Chem 3:127-34. 2007
    ..A different pharmacological profile was observed for the 2-azido derivatives, particularly in vivo...
  30. ncbi Antiinflammatory agents: new series of N-substituted amino acids with complex pyrimidine structures endowed with antiphlogistic activity
    O Bruno
    Dipartimento di Scienze Farmaceutiche dell Università, Genoa, Italy O Bruno
    Farmaco 54:95-100. 1999
    ..All the described products 2 and 3 showed an appreciable antiphlogistic activity, particularly 2b and 2c...
  31. ncbi N-Acyl-N-phenyl ureas of piperidine and substituted piperidines endowed with anti-inflammatory and anti-proliferative activities
    A Ranise
    Dipartimento di Scienze Farmaceutiche, Facolta di Farmacia, Genoa, Italy
    Farmaco 56:647-57. 2001
    ..Compound 5a showed a broad spectrum anti-cancer activity (at low micromolar concentrations), particulary significant against leukemia subpanel...
  32. ncbi Parallel synthesis, molecular modelling and further structure-activity relationship studies of new acylthiocarbamates as potent non-nucleoside HIV-1 reverse transcriptase inhibitors
    Andrea Spallarossa
    Dipartimento di Scienze Farmaceutiche, Universita di Genova, Viale Benedetto XV 3, I 16132 Genova, Italy
    Eur J Med Chem 44:2190-201. 2009
    ..Docking simulations were carried out to rationalize the most relevant SARs...
  33. ncbi N-substituted 3-(arylamino)-4,5-dihydro-2H-benz[g]indazol-2-yl acetamides with anti-inflammatory and analgesic activities
    S Schenone
    Dipartimento di Scienze Farmaceutiche dell Università di Genova, Italy
    Farmaco 55:383-8. 2000
    ..The title compounds showed only weak antiarrhythmic properties but good anti-inflammatory and antinociceptive activity, particularly evident in the morpholino derivative...
  34. ncbi N-acylated and N,N'-diacylated imidazolidine-2-thione derivatives and N,N'-diacylated tetrahydropyrimidine-2(1H)-thione analogues: synthesis and antiproliferative activity
    Sara Cesarini
    Dipartimento di Scienze Farmaceutiche, Universita di Genova, Viale Benedetto XV 3, I 16132 Genova, Italy
    Eur J Med Chem 44:1106-18. 2009
    ....
  35. ncbi Parallel one-pot synthesis and structure-activity relationship study of symmetric formimidoester disulfides as a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors
    Sara Cesarini
    Dipartimento di Scienze Farmaceutiche, Universita di Genova, Viale Benedetto XV 3, I 16132 Genova, Italy
    Bioorg Med Chem 16:6353-63. 2008
    ..74 microM. Compounds 19 and 33 were active at micromolar concentrations against the clinically relevant Y181C and/or K103R resistant mutants...
  36. ncbi Novel modifications in the series of O-(2-phthalimidoethyl)-N-substituted thiocarbamates and their ring-opened congeners as non-nucleoside HIV-1 reverse transcriptase inhibitors
    Andrea Spallarossa
    Dipartimento di Scienze Farmaceutiche, Universita di Genova, Viale Benedetto XV 3, I 16132 Genova, Italy
    Eur J Med Chem 44:1650-63. 2009
    ..Compound 56 combined the highest activity so far identified against Y181C (EC(50)=1.3 microM) with good potency against the K103R mutant (EC(50)=4.8 microM). Docking simulations helped to rationalize the SARs...
  37. ncbi Synthesis and biological evaluation of neutrophilic inflammation inhibitors
    Olga Bruno
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Viale Benedetto XV, Genova 3 16132, Italy
    Farmaco 59:223-35. 2004
    ..We report here synthesis, biological studies and some SAR considerations concerning the above mentioned compounds...
  38. ncbi 1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitors
    Olga Bruno
    Dipartimento di Scienze Farmaceutiche, Universita di Genova, Genova, Italy
    Bioorg Med Chem 17:3379-87. 2009
    ..In vivo compounds 2e and 2f, although to a lesser extent, at 50mg/kg os decreased granulocyte infiltration in zymosan-induced peritonitis in mice...
  39. ncbi Parallel synthesis of O-phenoxyethyl and O-adamantyl N-acyl thiocarbamates endowed with antiproliferative activity
    Andrea Spallarossa
    Dipartimento di Scienze Farmaceutiche, Universita di Genova, Genova, Italy
    Arch Pharm (Weinheim) 342:344-52. 2009
    ..Bioinformatic COMPARE analyses were carried out to identify possible mechanism(s) of action for acylthiocarbamate antiproliferative activity...
  40. ncbi Synthesis and pharmacological evaluation of 5H-[1]benzopyrano[4,3-d]pyrimidines effective as antiplatelet/analgesic agents
    Olga Bruno
    Dipartimento di Scienze Farmaceutiche Università degli Studi, V le Benedetto XV, 3 16132 Genova, Italy
    Bioorg Med Chem 12:553-61. 2004
    ..SAR considerations, also in comparison with a number of previously described compounds, were performed...
  41. ncbi New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms
    Olga Bruno
    Dipartimento di Scienze Farmaceutiche, University of Genoa, V le Benedetto XV, 3 16132 Genoa, Italy
    J Med Chem 52:6546-57. 2009
    ....
  42. ncbi Affinity prediction on A1 adenosine receptor agonists: the chemometric approach
    Paola Fossa
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Genoa, Italy
    Bioorg Med Chem 14:1348-63. 2006
    ..The evaluation 'a priori' of these predictors could therefore represent a useful tool in the screening of large libraries of compounds and in the rational design of new selective agonists...
  43. ncbi Synthesis of N-substituted-N-acylthioureas of 4-substituted piperazines endowed with local anaesthetic, antihyperlipidemic, antiproliferative activities and antiarrythmic, analgesic, antiaggregating actions
    Angelo Ranise
    Dipartimento di Scienze Farmaceutiche, Facolta di Farmacia, Universita degli Studi di Genova, Viale Benedetto XV 3, I 16132 Genova, Italy
    Farmaco 58:765-80. 2003
    ..13 microM) and NCI-H226 cell line (GI50: 1.03 microM), respectively...
  44. ncbi Synthesis and antiproliferative activity of basic thioanalogues of merbarone
    Angelo Ranise
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Viale Benedetto XV 3, 16132 Genova, Italy
    Bioorg Med Chem 11:2575-89. 2003
    ..In both cases the above compounds showed a decrease in potency. In enzyme assays, 11b and 14b turned out to be inhibitors of topoisonerase II as merbaron...
  45. ncbi Design, synthesis, SAR, and molecular modeling studies of acylthiocarbamates: a novel series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors structurally related to phenethylthiazolylthiourea derivatives
    Angelo Ranise
    Dipartimento di Scienze Farmaceutiche, Universita di Genova, Viale Benedetto XV 3, I 16132 Genova, Italy
    J Med Chem 46:768-81. 2003
    ..Analysis of these hypotetical complexes helps to rationalize some SARs and resistance data...
  46. ncbi Progress in 5H[1]benzopyrano[4,3-d]pyrimidin-5-amine series: 2-methoxy derivatives effective as antiplatelet agents with analgesic activity
    Olga Bruno
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Genoa, Italy
    Farmaco 57:753-8. 2002
    ..Comparison with a number of analogue benzopyrano[4,3-d]pyrimidine derivatives and some SAR consideration were reported...
  47. ncbi Synthesis, molecular modeling studies, and pharmacological activity of selective A(1) receptor antagonists
    Francesco Bondavalli
    Dipartimento di Scienze Farmaceutiche, , Viale Benedetto XV n.3, I-16132 Genova, Italy
    J Med Chem 45:4875-87. 2002
    ..All of the new compounds were tested for their affinity toward A(1), A(2a), and A(3) AR, showing interesting antagonistic activity and A(1) selectivity...
  48. ncbi Synthesis, antimicrobial activity and molecular modeling studies of halogenated 4-[1H-imidazol-1-yl(phenyl)methyl]-1,5-diphenyl-1H-pyrazoles
    Giulia Menozzi
    Dipartimento di Scienze Farmaceutiche, Universita di Genova, Viale Benedetto XV 3, 16132 Genova, Italy
    Bioorg Med Chem 12:5465-83. 2004
    ..The replacement, in these compounds, of chlorine with fluorine atoms led to inactive derivatives. Docking studies were carried out on the most active compounds, in order to rationalize the pharmacological results...
  49. ncbi Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives
    Angelo Ranise
    Dipartimento di Scienze Farmaceutiche, Universita di Genova, Viale Benedetto XV 3, I 16132 Genova, Italy
    J Med Chem 48:3858-73. 2005
    ..The docking model predictions were consistent with in vitro biological assays of the anti-HIV-1 activity of the TCs and related compounds synthesized...
  50. ncbi Construction and validation of a RET TK catalytic domain by homology modeling
    Tiziano Tuccinardi
    Dipartimento di Scienze Farmaceutiche, Universita di Pisa, Via Bonanno 6, I 56126 Pisa, Italy
    J Chem Inf Model 47:644-55. 2007
    ..Therefore, these models could be profitably used to filter off from large libraries new potential hit compounds able to target this enzyme...
  51. ncbi 2-Phenyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives: new potent inhibitors of fMLP-induced neutrophil chemotaxis
    Olga Bruno
    Dipartimento di Scienze Farmaceutiche, Universita di Genova, Genova, Italy
    Bioorg Med Chem Lett 17:3696-701. 2007
    ..All tested compounds showed strong inhibition of fMLP-OMe-induced chemotaxis, although they appeared unable to block degranulation and the fMLP-OMe-induced respiratory burst, and were inactive in binding experiments...
  52. ncbi Synthesis and biological evaluation of N-pyrazolyl-N'-alkyl/benzyl/phenylureas: a new class of potent inhibitors of interleukin 8-induced neutrophil chemotaxis
    Olga Bruno
    Dipartimento di Scienze Farmaceutiche, University of Genoa, V le Benedetto XV, 3 Genoa, Italy
    J Med Chem 50:3618-26. 2007
    ..Moreover, in the presence of the same derivatives, we observed a complete block of F-actin rise and pseudopod formation...
  53. ncbi Synthesis, antiplatelet and antithrombotic activities of new 2-substituted benzopyrano[4,3-d]pyrimidin-4-cycloamines and 4-amino/cycloamino-benzopyrano[4,3-d]pyrimidin-5-ones
    Olga Bruno
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Viale Benedetto XV, 3 16132 Genova, Italy
    Bioorg Med Chem 14:121-30. 2006
    ....
  54. ncbi New pyrazolo[3,4-b]pyridones as selective A(1) adenosine receptor antagonists: synthesis, biological evaluation and molecular modelling studies
    Paola Fossa
    Dipartimento di Scienze Farmaceutiche, , Viale Benedetto XV 3, 16132 Genova, Italy
    Org Biomol Chem 3:2262-70. 2005
    ..6 nM) and selectivity for A(3) AR. Molecular modelling and 3D-QSAR (CoMFA) studies carried out on the most active compounds gave further support to the pharmacological results...
  55. ncbi Synthesis of new piperazine-pyridazinone derivatives and their binding affinity toward alpha1-, alpha2-adrenergic and 5-HT1A serotoninergic receptors
    Laura Betti
    Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie, , Via Bonanno 6, I-56126 Pisa, Italy
    Bioorg Med Chem 14:2828-36. 2006
    ..However, several of the tested compounds also showed very good (in the nanomolar range) or moderate affinity toward the 5-HT1AR subtype...
  56. ncbi Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents
    Marco Radi
    Dipartimento Farmaco Chimico Tecnologico, Universita degli Studi di Siena, Via Alcide de Gasperi 2, I 53100 Siena, Italy
    Bioorg Med Chem Lett 18:1207-11. 2008
    ..Surprisingly, 6a was also proved to act as differentiating inducers in human promyelocytic leukemia cells (HL-60)...
  57. ncbi Pyrazolo[3,4-d]pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells
    Adriano Angelucci
    Dip Scienze Chirurgiche, University of L Aquila, 67100 L Aquila, Italy
    Eur J Cancer 42:2838-45. 2006
    ..Our data suggest a promising role for pyrazolo[3,4-d]pyrimidines c-Src inhibitors in the control of a highly invasive tumour phenotype...
  58. ncbi Pyrazolo-pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling
    Sandra Donnini
    Dipartimento di Biologia Molecolare, Universita degli Studi di Siena, Via Aldo Moro, 2, 53100, Siena, Italy
    Int J Cancer 120:995-1004. 2007
    ....
  59. ncbi Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation
    Fabio Carraro
    Dipartimento di Fisiologia, Sezione di Neuroimmunofisiologia, , Via Aldo Moro, I-53100, Siena, Italy
    J Med Chem 49:1549-61. 2006
    ..Moreover, molecular modeling simulations have been performed to hypothesize the way, at the molecular level, by which the inhibitors were able to act as antiproliferative agents...
  60. ncbi Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines
    Fabrizio Manetti
    Dipartimento Farmaco Chimico Tecnologico, Universita degli Studi di Siena, Via Alcide de Gasperi 2, I 53100, Siena, Italy
    J Med Chem 51:1252-9. 2008
    ..Insertion of halogen substituents with various substitution patterns, suggested by simulations, led to a significant improvement of leukemia cell growth inhibition and to an increase up to 1 order of magnitude of the affinity toward Abl...
  61. ncbi Synthesis and 3D QSAR of new pyrazolo[3,4-b]pyridines: potent and selective inhibitors of A1 adenosine receptors
    Fabrizio Manetti
    Dipartimento Farmaco Chimico Tecnologico, , Via Aldo Moro, I-53100 Siena, Italy
    J Med Chem 48:7172-85. 2005
    ..To rationalize the relationships between structure and affinity of the novel compounds, a 3D QSAR model was also generated starting from compounds belonging to different classes of known A1AR antagonists...
  62. ncbi N-(thiazol-2-yl)-2-thiophene carboxamide derivatives as Abl inhibitors identified by a pharmacophore-based database screening of commercially available compounds
    Fabrizio Manetti
    Dipartimento Farmaco Chimico Tecnologico, Universita degli Studi di Siena, Via Alcide de Gasperi 2, I 53100, Siena, Italy
    Bioorg Med Chem Lett 18:4328-31. 2008
    ..Moreover, affinity of the new compounds was also rationalized in terms of their interactions with the enzyme...
  63. ncbi Pyrazolo[3,4-d]pyrimidines endowed with antiproliferative activity on ductal infiltrating carcinoma cells
    Fabio Carraro
    Dipartimento di Fisiologia, , , Via Aldo Moro, I-53100 Siena, Italy
    J Med Chem 47:1595-8. 2004
    ..The ability of such compounds to significantly reduce 8701-BC cell proliferation suggests that this scaffold could be a promising lead for the development of antitumoral agents able to block Src phosphorylation of breast cancer cells...
  64. ncbi Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells
    Adriano Spreafico
    Universita degli Studi di Siena, Dipartimento di Biologia Molecolare, Via Fiorentina 1, 53100 Siena, Italy
    FASEB J 22:1560-71. 2008
    ..These results show that human osteosarcoma had Src-dependent proliferation and that modulation of Src activity may be a therapeutic target of this new compound with low toxicity for nonneoplastic cells...
  65. ncbi Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice
    Fabrizio Manetti
    Dipartimento Farmaco Chimico Tecnologico, Universita degli Studi di Siena, Siena, Italy
    J Med Chem 50:5579-88. 2007
    ..These experimental findings make the new compound an interesting hit in the field of bone-related diseases...
  66. ncbi Inhibition of Bcr-Abl phosphorylation and induction of apoptosis by pyrazolo[3,4-d]pyrimidines in human leukemia cells
    Fabrizio Manetti
    Dipartimento Farmaco Chimico Tecnologico, Universita degli Studi di Siena, Via Alcide de Gasperi 2, 53100 Siena, Italy
    ChemMedChem 2:343-53. 2007
    ..Finally, molecular modeling simulations were also performed to hypothesize the binding mode of the compounds into the Abl binding site...
  67. ncbi A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors
    Fabrizio Manetti
    Dipartimento Farmaco Chimico Tecnologico, , Via Alcide de Gasperi 2, I-53100, Siena, Italy
    J Med Chem 49:3278-86. 2006
    ..Such biological data suggested that the computational protocol is an efficient tool for identifying new hits toward both Src and Abl...
  68. ncbi Exploring the molecular basis of selectivity in A1 adenosine receptors agonists: a case study
    Fabrizio Giordanetto
    Centre for Computational Science, Department of Chemistry, Queen Mary University of London, Mile End Road, London E1 4NS, United Kingdom
    J Comput Aided Mol Des 17:39-51. 2003
    ..The models presented here provide a detailed molecular map for the selective stimulation of the adenosine A1 receptor subtype and a steady basis for the rational design of new A1 selective ligands...